Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

@article{Buse2004EffectsOE,
  title={Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.},
  author={John B Buse and Robert R. Henry and Jenny Han and Dennis D. Kim and Mark S Fineman and Alain D. Baron},
  journal={Diabetes care},
  year={2004},
  volume={27 11},
  pages={2628-35}
}
OBJECTIVE This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy. RESEARCH DESIGN AND METHODS This was a triple-blind, placebo-controlled, 30-week study conducted at 101 sites in the U.S. After a 4-week, single-blind, placebo lead-in period, 377 subjects were randomized (60% men, age 55 +/- 11 years, BMI 33 +/- 6 kg/m(2), HbA(1c) 8.6 +/- 1.2… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
411 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 411 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…